Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;114:186-193.
doi: 10.1016/j.ejpb.2017.01.018. Epub 2017 Feb 1.

Antitumoral Effect and Reduced Systemic Toxicity in Mice After Intra-Tumoral Injection of an in Vivo Solidifying Calcium Sulfate Formulation With Docetaxel

Affiliations

Antitumoral Effect and Reduced Systemic Toxicity in Mice After Intra-Tumoral Injection of an in Vivo Solidifying Calcium Sulfate Formulation With Docetaxel

Stefan Grudén et al. Eur J Pharm Biopharm. .

Abstract

Background: Docetaxel is a cytostatic agent approved for treatment of non-small cell lung cancer as well as other cancers. Although docetaxel is an effective cytostatic agent, its effectiveness in clinical practice is associated with a variety of acute and long term side-effects. To overcome systemic side-effects, a slow release formulation based on calcium sulfate with docetaxel for intra-tumoral administration was developed.

Methods: Two formulations with the calcium sulfate NanoZolid technology were generated with a twofold difference in docetaxel drug load. The formulations were injected intra-tumorally as a paste which solidified within the tumor. The effects of the two intra-tumoral injection formulations were tested in female mice (n=60) inoculated with subcutaneous Lewis lung carcinoma cells. The two formulations were compared to systemic intraperitoneal injection of docetaxel and a placebo formulation without docetaxel. Tumor volumes were measured and systemic side-effects were evaluated using body weight and cell counts from whole blood as well as plasma concentrations.

Results: Both docetaxel formulations showed a significantly higher antitumor efficacy compared to placebo, which was comparable to that of systemic administration of docetaxel. Moreover, the intra-tumoral formulations with docetaxel showed reduced systemic toxicity compared to systemic treatment, including less weight loss and no decrease in blood cell counts.

Conclusions: The results suggest that intra-tumoral slow release calcium sulfate based formulations with docetaxel can be an alternative strategy as an efficient local antitumoral treatment with reduced systemic toxicity.

Keywords: Bioresorbable; Calcium sulfate; Docetaxel; Intratumoral; Lewis lung carcinoma; Non-small cell lung cancer; Slow release formulation.

Similar articles

See all similar articles

Cited by 1 article

MeSH terms

LinkOut - more resources

Feedback